COH-SR4 是一种 AMPK 活化剂。COH-SR4 对白血病、黑色素瘤、乳腺癌和肺癌显示出强大的抗增殖活性。COH-SR4 通过激活 AMPK 来抑制脂肪细胞分化，有望用于肥胖及代谢紊乱相关的研究。

COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.

Solid

AMPK

COH-SR4 (1-5 μM; 24 hours) results in a dose-dependent increase in the phosphorylation of AMPK and its substrate ACC in 3T3-L1 preadipocytes, as well as in cancer cells such as HL-60, HeLa, MCF-7.
COH-SR4 (3-5 μM; 7 days) significantly inhibits 3T3-L1 adipocyte differentiation in a dose-dependent manner.
COH-SR4 (1-5 μM; 24 hours) promotes cell G1 cycle arrest.
COH-SR4 significantly reduces intracellular lipid accumulation and downregulates the expression of key adipogenesis-related transcription factors and lipogenic proteins.
has not independently confirmed the accuracy of these methods. They are for reference only.

COH-SR4 (5 mg/kg; i.g.; 3x/week; for 6 weeks) reduces body weight and fat mass in high fat diet (HFD) obese mice without affecting food intake.
COH-SR4 improves glycemic control and dyslipidemia in HFD obese mice.
COH-SR4 decreases adipose tissue hypertrophy and affects circulating adipokine levels in HFD obese mice.
COH-SR4 prevents hepatic lipid accumulation and fatty liver in HFD obese mice.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. James L Figarola, et al. Small?molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation. Int J Mol Med. 2013 May;31(5):1166-76.
[2]. James Lester Figarola, et al. COH-SR4 Reduces Body Weight, Improves Glycemic Control and Prevents Hepatic Steatosis in High Fat Diet-Induced Obese Mice. PLoS One. 2013; 8(12): e83801.

In Vitro: DMSO : 125 mg/mL (357.11 mM; Need ultrasonic)配制储备液